Steve DeMartino
Analyst · B. Riley & Company. Your line is open
Thanks, Bart. Good afternoon everyone. 2016 first quarter net sales were $14.4 million compared to $16.2 million in the year-ago quarter. As Bart pointed out earlier, our ability to deliver year-over-year gross margin expansion of 80 basis points in the quarter clearly demonstrates the benefits of the company’s strategy, which is now focused on high-margin high-growth products such as Epicentral and AccuDate. We also continue to position the company for further growth in 2016, thanks to our continued investment and the development, sales and support of these newest product lines. Looking at our sales by market for the first quarter, food safety POS and banking sales of $3.1 million, grew 41% or $900,000 over last year’s first quarter. Sales in the period largely reflect McDonald’s undergoing rollout of our Ithaca 9000 printer throughout their stores. Important, the Ithaca 9000 has become an integral part of McDonald’s technology solution and supported their multiple new product initiatives such as customized burgers and other cook while you wait items, which should lead to strong sales for us throughout 2016. On the food safety side of the business, sales of food safety terminals were essentially flat compared with the year-ago period, as we continue to build a foundation for long-term growth. As Bart mentioned earlier, we have now won 44 distinct restaurant brands and concepts that together represent a total potential addressable opportunity of over 80,000 terminals, and we expect to execute on these initial opportunities over the next several years. Casino and gaming sales were down slightly by approximately $200,000 or 3% year-over-year to $5.4 million. However, as we have seen in the past four consecutive quarters, this business continues to benefit from strong domestic sales of our Epic casino and gaming printers, evidenced by a 29% increase in domestic printer sales in the quarter. Given the sluggish domestic market, TransAct is clearly taking share in the domestic gaming market as our Epic 950 printer further solidifies its industry-leading position. First quarter results also benefited from the rollout of two new domestic Epicentral deployments in the period, including Foxwoods Resort Casino right here in Connecticut. The increase in domestic printer sales and the two Epicentral rollouts was offset by weakness in sales of our casino and gaming printers to international markets. Lottery sales were down 27% to $2.9 million from $4 million in the first quarter last year. The year-ago period benefited from unusually high GTECH sales volumes, including a significant one-time order for a custom printer that did not repeat. We continue to believe that our recent ability to market our Epic 3000 lottery printer to the global lottery market positions TransAct to grow our overall base of lottery customers. Printrex products generated revenue of approximately $150,000 compared to approximately $700,000 in the year-ago quarter as severely depressed oil and gas prices continued to have a negative impact on our oil and gas drilling activity. We believe Printrex printer sales will remain under pressure throughout 2016. And as we mentioned over the past several quarters, we have taken the necessary steps to align our cost structure for this business with the current revenue level. And finally, TSG sales were down 26% year-over-year to $2.7 million. The TSG business was negatively impacted by lower lottery spare part sales to IGT, as well as continued weakness in sales of Printrex consumables related to the ongoing weakness in oil and gas prices. Gross margin for the first quarter improved to 41%, 80 basis points higher than our first quarter 2015 gross margin of 40.2%. Our gross margin continues to benefit from a favorable sales mix of higher margin food safety terminals in Epicentral software sales, as well as the decline in sales of our lower margin lottery printers. As we look to the balance of 2016, we believe that executing against our current AccuDate opportunities of over 80,000 potential terminals will grow this product line as a percentage of our overall sales and that higher sales of these terminals in concert with further deployments of our Epicentral promotion bonusing software system will enable us to further expand our gross margin. As we said last quarter, overtime, we believe gross margins can climb to the mid-to-high 40% range and even touch 50% given the right sales mix. Total operating expenses were $4.9 million for the first quarter, compared to $6.3 million a year-ago. Excluding $1.7 million of legal fees related to the now settled Avery Dennison lawsuit in the prior year period, our operating expenses in the quarter increased approximately $400,000 or 9% year-over-year as we made targeted investments during the first quarter in support and development of our AccuDate and Epicentral product lines. Engineering design and product development expenses for the first quarter were up $368,000 or 42% year-over-year as we continue to invest in the development team supporting our key Epicentral and AccuDate product lines. Selling and marketing expenses for the first quarter were down slightly by $30,000 or 2% to $1.8 million as our recent efforts to reduce expenses across the business were partially offset by investments in support of our newer products. And G&A expenses for the first quarter were $1.9 million, up 4% from the prior-year period. Operating income for the first quarter of 2016 was $939,000 or 6.5% of sales compared to operating income of $217,000 or 3.3% of sales in the year-ago quarter. Operating income in the first quarter of last year included approximately $1.7 million of legal fees related to the Avery Dennison lawsuit. Both GAAP and adjusted diluted EPS for the 2016 first quarter were $0.08 compared to GAAP EPS of $0.02 and adjusted EPS of $0.16 in the year-ago period. Adjusted EBITDA for the first quarter 2016 was $1.4 million compared to $2.5 million in the first quarter last year. And turning to the balance sheet, we ended the quarter with $2.9 million in cash and no debt outstanding. We returned a total of approximately $1.1 million of capital to shareholders during the 2016 first quarter to our quarterly cash dividend of $0.08 per share and the repurchase of approximately $510,000 of TransAct shares at an average price of $8.09 per share. The repurchases we made during the quarter were pursuant to our new $5 million authorization that we announced in late February, under which we have about $4.5 million remaining as of the end of March. As Bart mentioned a few minutes ago, TransAct remains focused on 2016 and driving Epicentral and AccuDate sales and further augmenting these products through the introduction of new features in the case of Epicentral and the introduction of a new third AccuDate food safety terminal. While we expect Printrex to remain a drag on our overall business and we continue to de-emphasize our legacy products, we still expect gross margin to expand as our new higher margin products growth represent a greater percentage of our overall sales. 2016 remains a year of opportunity for TransAct and we are well-positioned financially to exploit these opportunities. And at this point, I would like to give the call back to Bart for some final remarks. Bart?